Assuntos
Anticorpos Monoclonais Humanizados , Azetidinas , Dermatite Atópica , Purinas , Pirazóis , Sulfonamidas , Humanos , Dermatite Atópica/tratamento farmacológico , Estudos Retrospectivos , Pirazóis/administração & dosagem , Pirazóis/uso terapêutico , Pirazóis/efeitos adversos , Azetidinas/uso terapêutico , Azetidinas/administração & dosagem , Anticorpos Monoclonais Humanizados/administração & dosagem , Anticorpos Monoclonais Humanizados/uso terapêutico , Criança , Masculino , Sulfonamidas/uso terapêutico , Sulfonamidas/administração & dosagem , Feminino , Purinas/administração & dosagem , Purinas/uso terapêutico , Adolescente , Substituição de Medicamentos , Resultado do Tratamento , Pré-Escolar , Índice de Gravidade de Doença , Fármacos Dermatológicos/uso terapêutico , Fármacos Dermatológicos/administração & dosagemRESUMO
Israel is endemic for Old-World cutaneous leishmaniasis. The most common species is Leishmania major. However, the available treatment options are limited. This study's objective was to compare the authors' experience with different antimony intralesional treatments of Leishmania major cutaneous leishmaniasis. A retrospective evaluation was undertaken for cases of Leishmania major cutaneous leishmaniasis treated by pentavalent antimony in a university-affiliated medical centre in Israel. The previous treatment of intralesional sodium stibogluconate (Pentostam®) was compared with the current treatment of meglumine antimoniate (Glucantime®). One hundred cases of cutaneous leishmaniasis were treated during the study period, of whom 33 were treated with intralesional sodium stibogluconate and 67 were treated with intralesional meglumine antimoniate. The patients were 78 males and 22 females, mean age 24 (range 10-67) and there was a total of 354 skin lesions. Within 3 months from treatment, 91% (30/33) of the intralesional sodium stibogluconate group and 88% (59/67) of the intralesional meglumine antimoniate group had complete healing of the cutaneous lesions after an average of 3 treatment cycles (non-statistically significant). In conclusion, the 2 different medications have the same efficacy and safety for treating cutaneous leishmaniasis. Pentavalent antimoniate intralesional infiltration treatment is safe, effective, and well tolerated with minimal side effects for Old-World cutaneous leishmaniasis.
Assuntos
Gluconato de Antimônio e Sódio , Antiprotozoários , Injeções Intralesionais , Leishmania major , Leishmaniose Cutânea , Antimoniato de Meglumina , Humanos , Antimoniato de Meglumina/administração & dosagem , Leishmaniose Cutânea/tratamento farmacológico , Leishmaniose Cutânea/parasitologia , Leishmaniose Cutânea/diagnóstico , Feminino , Masculino , Gluconato de Antimônio e Sódio/administração & dosagem , Estudos Retrospectivos , Adulto , Antiprotozoários/administração & dosagem , Antiprotozoários/efeitos adversos , Pessoa de Meia-Idade , Leishmania major/efeitos dos fármacos , Idoso , Adulto Jovem , Adolescente , Resultado do Tratamento , Criança , Fatores de Tempo , Israel , Meglumina/administração & dosagem , Compostos Organometálicos/administração & dosagemRESUMO
BACKGROUND: Psoriasis and psoriatic arthritis can present simultaneously or separately in children and may pose a diagnostic challenge. OBJECTIVE: To compare the dermatological manifestations in pediatric psoriatic patients with and without arthritis. METHODS: A retrospective case-control study of psoriatic patients ≤ 18 years old at Sheba Medical Center was conducted between 2011 and 2021. Patients with psoriatic arthritis versus psoriasis-only were compared according to body surface area (BSA) involvement, cutaneous distribution, severity of skin disease, response to treatment and related side effects. RESULTS: The study cohort included 29 psoriatic arthritis and 64 psoriasis-only patients matched by age and sex. The psoriasis-only group had a significantly higher mean BSA (19.7%, SD ± 18.7) than the psoriatic arthritis group (6.1%, SD ± 11.4), (p = 0.029). The skin distribution differed with the psoriasis group showing more involvement of the extremities, scalp, trunk, and genitals. Both groups primarily experienced partial responses to methotrexate, whereas the psoriasis group mainly saw complete responses to biologics. Adverse events were rare, with a higher incidence in the psoriasis group. CONCLUSION: This retrospective study highlights the differences in cutaneous disease characteristics, severity, and treatment response in pediatric patients with psoriasis and psoriatic arthritis, providing valuable insights for diagnosis and disease course in the pediatric population.